Silexion Therapeutics Ltd. (SLXNW)
IL — Healthcare Sector
Automate Your Wheel Strategy on SLXNW
With Tiblio's Option Bot, you can configure your own wheel strategy including SLXNW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
About Silexion Therapeutics Ltd. (SLXNW)
- IPO Date 2024-08-16
- Website https://silexion.com
- Industry Biotechnology
- CEO Ilan Hadar
- Employees 11
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.